OBJECTIVES: Syndecan-1 is a transmembrane proteoglycan involved in various biological processes. Its extracellular, transmembrane and cytoplasmic domains may all participate in signal transduction. The aim of this study was to investigate the biological roles of these domains of syndecan-1. MATERIALS AND METHODS: We transfected cells of two mesenchymal tumour cell lines with a full-length syndecan-1 construct and three truncated variants, namely 78 construct lacking the EC domain with exception of DRKE sequence; 77 construct lacking extracellular the whole domain and RMKKK corresponding to a short cytoplasmic motif. Subcellular distribution was revealed using confocal laser microscopy. Overexpression of the constructs was verified using real-time RT-PCR and by FACS analysis and effects of syndecan-1 on cell behaviour were explored. Cell cycle analysis allowed for dissection of mechanisms regulating cell proliferation. RESULTS: Overexpression of syndecan-1 influenced expression profile of the other syndecan members, and decreased tumour cell proliferation significantly by two mechanisms, as follows: increased length of G0/G1 phase was the most evident change in RMKKK and 77 transfectants, whereas prolonged S phase was more obvious in full-length transfectants. Overexpression of syndecan-1 changed the tumour cell morphology in an epithelioid direction. CONCLUSIONS: Both full-length and truncated syndecan-1 inhibited proliferation of the mesenchymal tumour cells, providing new insights into the importance for cancer growth of different functional domains of this proteoglycan.
OBJECTIVES:Syndecan-1 is a transmembrane proteoglycan involved in various biological processes. Its extracellular, transmembrane and cytoplasmic domains may all participate in signal transduction. The aim of this study was to investigate the biological roles of these domains of syndecan-1. MATERIALS AND METHODS: We transfected cells of two mesenchymal tumour cell lines with a full-length syndecan-1 construct and three truncated variants, namely 78 construct lacking the EC domain with exception of DRKE sequence; 77 construct lacking extracellular the whole domain and RMKKK corresponding to a short cytoplasmic motif. Subcellular distribution was revealed using confocal laser microscopy. Overexpression of the constructs was verified using real-time RT-PCR and by FACS analysis and effects of syndecan-1 on cell behaviour were explored. Cell cycle analysis allowed for dissection of mechanisms regulating cell proliferation. RESULTS: Overexpression of syndecan-1 influenced expression profile of the other syndecan members, and decreased tumour cell proliferation significantly by two mechanisms, as follows: increased length of G0/G1 phase was the most evident change in RMKKK and 77 transfectants, whereas prolonged S phase was more obvious in full-length transfectants. Overexpression of syndecan-1 changed the tumour cell morphology in an epithelioid direction. CONCLUSIONS: Both full-length and truncated syndecan-1 inhibited proliferation of the mesenchymal tumour cells, providing new insights into the importance for cancer growth of different functional domains of this proteoglycan.
Authors: F Numa; K Hirabayashi; N Tsunaga; H Kato; K O'Rourke; H Shao; C Stechmann-Lebakken; J Varani; A Rapraeger; V M Dixit Journal: Cancer Res Date: 1995-10-15 Impact factor: 12.701
Authors: Szilvia Szabo; Yi Xu; Roberto Romero; Tibor Fule; Katalin Karaszi; Gaurav Bhatti; Tibor Varkonyi; Ildiko Varkonyi; Tibor Krenacs; Zhong Dong; Adi L Tarca; Tinnakorn Chaiworapongsa; Sonia S Hassan; Zoltan Papp; Ilona Kovalszky; Nandor Gabor Than Journal: Virchows Arch Date: 2013-06-27 Impact factor: 4.064
Authors: Tünde Szatmári; Filip Mundt; Ghazal Heidari-Hamedani; Fang Zong; Elena Ferolla; Andrey Alexeyenko; Anders Hjerpe; Katalin Dobra Journal: PLoS One Date: 2012-10-29 Impact factor: 3.240
Authors: Fang Zong; Eleni Fthenou; Filip Mundt; Tünde Szatmári; Ilona Kovalszky; László Szilák; David Brodin; George Tzanakakis; Anders Hjerpe; Katalin Dobra Journal: PLoS One Date: 2011-06-23 Impact factor: 3.240
Authors: E V Grigorieva; T Y Prudnikova; N V Domanitskaya; L A Mostovich; T V Pavlova; V I Kashuba; E R Zabarovsky Journal: Br J Cancer Date: 2011-06-07 Impact factor: 7.640
Authors: Bálint Péterfia; Tibor Füle; Kornélia Baghy; Krisztina Szabadkai; Alexandra Fullár; Katalin Dobos; Fang Zong; Katalin Dobra; Péter Hollósi; András Jeney; Sándor Paku; Ilona Kovalszky Journal: PLoS One Date: 2012-06-26 Impact factor: 3.240
Authors: Fang Zong; Eleni Fthenou; Nina Wolmer; Péter Hollósi; Ilona Kovalszky; László Szilák; Carolin Mogler; Gustav Nilsonne; Georgios Tzanakakis; Katalin Dobra Journal: PLoS One Date: 2009-10-05 Impact factor: 3.240